GlassScriptPhysician profile
Mark R Boelkins
NPI 1942396437
$455.93
in general payments reported to CMS, 2019-2025
8 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2021: $37.12 · 2022: $123 · 2023: $16.15 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $160.31 | 2019 | |
| Calliditas Therapeutics US INC. | $119.62 | 2025 | Tarpeyo |
| Veloxis Pharmaceuticals, INC. | $56.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $38.62 | 2022-2023 | Flumist Quadrivalent |
| Alnylam Pharmaceuticals INC. | $29.60 | 2022 | |
| Horizon Therapeutics Plc | $20.59 | 2021 | |
| Aurinia Pharma U.S., INC. | $16.53 | 2021 | |
| Glaxosmithkline, LLC. | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Boelkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.